Search Results - "Larrey D"

Water-condensation rate critical in predicting, preventing TLC in wet-gas lines.

Authors: Gunaltun, Y. M. Larrey, D.

Source: Oil & Gas Journal; July 10 2000, Vol. 98 Issue 28, p58-63, 6p

This result is not displayed to guests.
Login for full access.

Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study.

Authors: Gulmez SE Larrey D Pageaux GP et al.

Source: Drug Safety. 2013, Vol. 36 Issue 2, p135-144. 10p.

URL: 85399599

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.

Authors: Forestier N Larrey D Marcellin P et al.

Source: Journal of Infectious Diseases. 8/15/2011, Vol. 204 Issue 4, p601-608. 8p.

Lomitapide hepatic safety: A long term retrospective analysis in patients with homozygous familial hypercholesterolaemia.

Authors: Larrey, D. D'Erasmo, L. O'Brien, S. et al.

Source: Atherosclerosis (00219150). 2023 Supplement 1, Vol. 379, pS17-S17. 1p.

Acute pancreatitis induced by herbs of Provence.

Authors: DAVID, X. BORIES, P. PARELON, G. et al.

Source: Lancet. 2/2/1991, Vol. 337 Issue 8736, p311-311. 1/2p.

1147 VIROLOGICAL RESPONSE AND RELAPSE RATES IN FRENCH CHC PATIENTS TREATED WITH PEGINTERFERON ALFA-2A/RIBAVIRIN: A SUB-ANALYSIS OF THE FINAL POPULATION FROM THE PROPHESYS STUDY

Authors: Ouzan, D. Larrey, D. Habersetzer, F. et al.

Source: Journal of Hepatology. Apr2012 Supplement, Vol. 56 Issue s2, pS453-S453. 1p.

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

Authors: Rouzier, R. Larrey, D. Gane, E.J. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS28-S28. 1p.

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

Authors: Larrey, D. Lohse, A. de Ledinghen, V. et al.

Source: Journal of Hepatology. Apr2010 Supplement 1, Vol. 52, pS466-S466. 1p.

1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Authors: Larrey, D. Benhamou, Y. Lohse, A.W. et al.

Source: Journal of Hepatology. Apr2009 Supplement 1, Vol. 50, pS383-S384. 0p.

85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)

Authors: Forestier, N. Larrey, D. Marcellin, P. et al.

Source: Journal of Hepatology. Apr2009 Supplement 1, Vol. 50, pS35-S35. 1p.

803 EFFECTS OF SYSTEMATIC NURSE-PROVIDED THERAPEUTIC EDUCATION ON ADHERENCE AND EFFICIENCY OF PEG-INTERFERON-ALPHA2A (PEGASYS®)-RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C (PEGOBS PROTOCOL)

Authors: Larrey, D. Salse, A. Pageaux, G.P. et al.

Source: Journal of Hepatology. May2008 Supplement 2, Vol. 48, pS300-S300. 1p.

[722] UTILITY OF THE ROUSSEL UCLAF CAUSALITY

Authors: Larrey, D. Lewis, J.H. Olsson, R. et al.

Source: Journal of Hepatology. Apr2007, Vol. 46, pS272-S272. 1p.

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study.

Authors: Lampertico, Pietro Berg, Thomas Buti, Maria et al.

Source: Alimentary Pharmacology & Therapeutics. Aug2020, Vol. 52 Issue 3, p500-512. 13p. 1 Diagram, 2 Charts, 4 Graphs.

Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes

Authors: Larrey, D. Horsmans, Y. Lannes, D. et al.

Source: Xenobiotica. Dec1991, Vol. 21 Issue 12, p1559. 0p.

Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients.

Authors: Dereure, O. Raison-Peyron, N. Larrey, D. et al.

Source: British Journal of Dermatology. Dec2002, Vol. 147 Issue 6, p1142-1146. 5p.

The negative impact of HBV/ HCV coinfection on cirrhosis and its consequences.

Authors: Pol, S. Haour, G. Fontaine, H. et al.

Source: Alimentary Pharmacology & Therapeutics. Dec2017, Vol. 46 Issue 11/12, p1054-1060. 7p.

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

Authors: Boursier, J. Ducancelle, A. Vergniol, J. et al.

Source: Journal of Viral Hepatitis. Dec2015, Vol. 22 Issue 12, p1002-1010. 9p.

Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.

Authors: BONNY, C. FONTAINE, H. POYNARD, T. et al.

Source: Alimentary Pharmacology & Therapeutics. Aug2006, Vol. 24 Issue 4, p593-600. 8p. 5 Charts.

Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences.

Authors: Pascussi, J.-M. Gerbal-Chaloin, S. Drocourt, L. et al.

Source: Xenobiotica. Jul2004, Vol. 34 Issue 7, p633-664. 32p.